13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • KEYNOTE-826

    Acronym: 

    KEYNOTE-826

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase III Tumour Stream Ovarian Cancer
    Age Range 18 years and older Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Ovarian Cancer
    Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase 3 randomized , double-blind, placebo-controlled trial of pembrolizumab (MK-3475) plus chemotherapy versus chemotherapy plus placebo for the first-line treatment of persistent, recurrent, or metastatic cervical cancer

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Not Yet Recruiting